Efficacy, safety and accessibility to CAR-T therapy for lymphomas
EHA Library. Borchmann P. 06/15/18; 219075 Topic: 3A B-cell neoplasms and B-cell disorders
Peter Borchmann
Peter Borchmann
Contributions
Learning Objectives
THIS MANUSCRIPT IS PUBLISHED AS AN OFFICIAL SUPPLEMENT OF HEMASPHERE.

Pier Luigi Zinzani - Chair Introduction
The complex relationship between the immune system and cancer development has been the subject of investigation for decades. Improved understanding of the interactions between cancer cells and the immune system combined with technological advances has led to the development of novel types of immunotherapies. This progress, combined with technological advances, has led to the development of novel immunotherapies which have demonstrated remarkable efficacy for the treatment of cancer. In lymphomas three of these new immunotherapies appear to be particularly promising: immune checkpoint inhibitors, Chimeric Antigen Receptor (CAR) T-cells, and lymphoma neoantigens. Each of these approaches has its own advantages and inconveniences. Furthermore, they benefit different patients. Some of these immunotherapies have already been granted approval by the FDA for hematologic malignancies (anti-PD1 antibodies in Hodgkin lymphoma, and CAR T cells in diffuse large B-cell lymphoma). In the future, these approvals are likely to be extended to other histological subtypes of non-Hodgkin lymphomas. Thus, these new immunotherapies should be seen as complementary rather than competitive. This is the beginning of a new and exciting era in which each patient will be offered a “personalized immunotherapy” based on the status of his tumor and immune system.

Learning Objectives of the article
- To acknowledge immune checkpoint inhibitors.
- To acknowledge CAR T cells.
- To acknowledge lymphoma neoantigens.

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies